phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced updated long-term follow-up data from the pivotal study of PAPZIMEOS(tm) (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP).

June 1, 2026


June 11 2026

June 10 2026

June 9 2026

June 8 2026

June 7 2026

June 5 2026

June 4 2026

June 3 2026

June 2 2026

June 1 2026

May 31 2026

May 30 2026

May 29 2026

Angell Street Psychiatry
Copyright 2026 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy